Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Knowing the average retirement savings for 30-year-olds helps gauge your financial health. Learn the benchmarks to aim for as you save.
23,529 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Curious about Cerebras stock and its three-year outlook? This guide breaks down growth drivers, risks, and three scen...
As 2026 unfolds, I’m leaning into one magnificent ETF that fits my high-conviction approach. Here’s why this fund sta...
Biotech shares retreat as Moderna slides 11% and ImmunityBio falls, with Sarepta also sinking amid a broad market rot...
Two Vanguard long-duration bond ETFs sit at the center of many fixed-income decisions: VGLT (Long-Term Treasury) and ...
Hims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Futures point to a weaker start as AI fears push U.S. stocks being battered lower, even as international markets rall...
Bitcoin staged a striking break from a long-standing pattern, defying a rising dollar as ETF inflows surged. Analysts...
Two consumer brands buck a slowing staples backdrop, delivering growth driven by more transactions and expanded house...
As money flows into SPY accelerate, four small-cap ETFs are quietly delivering outsized gains. This report breaks dow...
Take a practical tour of arcutis (arqt) 2026 earnings, from revenue mix and margins to pipeline progress and risk fac...
This article breaks down Rekor’s Q1 2026 earnings call in plain English. Learn what the numbers mean for the rekor (r...